Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07503821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular Synovitis

Study acronym: SYVIPRO
StatusRecruiting
PhaseNot applicable
Started2026-09
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 4 months later Apr 2030 → Sep 2030
See other at-risk trials from Nantes University Hospital

Amendment history

2026-09-10
notable
Study Status, Eligibility, Contacts/Locations v1
Recruitment opened
Primary completion pushed: 2030-04 → 2030-09
Completion pushed: 2030-04 → 2030-09
Start date2026-04→2026-09
Eligibility criteria-7 characters
[...] enefiting from a social security scheme Exclusion Criteria: Minors Pregnant women Nursing mothers Protected patients: patients [...]
Study sitesdetails revised at 3 of 3 sites
2026-03-26
minor
Original filing
Pigmented villonodular synovitis (PVNS) is a rare joint disease caused by the proliferation of synovial tissue, leading to significant pain and joint destruction. It typically begins between the ages of 30 and 50 and significantly affects patients' functionality. The proliferation is due to somatic mutations in some fibroblastic cells within the tissue, which triggers a massive recruitment of inflammatory cells. The condition is considered a benign tumor of the synovial membrane with a major inflammatory component. Diagnosing PVNS requires synovial tissue analysis, obtained either through surgical excision or guided needle biopsy. This biopsy technique, done as an outpatient procedure, is well tolerated and helps confirm the diagnosis before treatment. Our goal is to better understand this disease and determine if the analysis of synovial tissue could serve as a useful biomarker for patient management in the context of personalized medicine.
Trial Details
NCT Number NCT07503821
Lead Sponsor Nantes University Hospital
Conditions Synovitis Villonodular
Enrollment 30 participants
Start Date 2026-09
Primary Completion 2030-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-09-14